CorMedix
CRMD
85 hedge funds and large institutions have $73.4M invested in CorMedix in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
23% more capital invested
Capital invested by funds: $59.4M → $73.4M (+$13.9M)
6% more funds holding
Funds holding: 80 → 85 (+5)
6% more call options, than puts
Call options by funds: $749K | Put options by funds: $707K
0.83% more ownership
Funds ownership: 34.25% → 35.08% (+0.83%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$1.83M |
| 2 |
Morgan Stanley
New York
|
+$309K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$154K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$117K |
| 5 |
VF
Virtu Financial
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$355K |
| 2 |
Barclays
London,
United Kingdom
|
-$182K |
| 3 |
Two Sigma Advisers
New York
|
-$158K |
| 4 |
Two Sigma Investments
New York
|
-$151K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$132K |
CRMD Hedge Fund Activity: Q1 2022 in Review
85 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2022, worth a combined $73.4M — up 23% from $59.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CRMD positions and 9 closed out — a net gain of 5 holders — while 20 added to existing stakes and 26 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $1.83M. The largest seller was BlackRock, cutting an estimated $355K.
- 85 institutional investors held CorMedix (CRMD) as of Q1 2022, up from 80 in Q4 2021.
- Funds reported $73.4M of CorMedix stock for Q1 2022, up 23% quarter-over-quarter.
- 14 funds opened new CorMedix positions in Q1 2022 and 9 closed out, a net change of +5 holders.
- The largest CorMedix buyer in Q1 2022 was Nomura Holdings, an estimated $1.83M added.
- The largest CorMedix seller in Q1 2022 was BlackRock, an estimated $355K sold.
Based on aggregated 13F filings for Q1 2022.